

POLICY NUMBER: RX.PA.043.MPC REVISION DATE: 12/2021 PAGE NUMBER: 1 of 2

RX.PA.043.MPC Dalvance

The purpose of this policy is to define the prior authorization process for Dalvance[®] (dalbavancin)

Dalvance[®] (dalbavancin) is indicated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms.

PROCEDURE

A. Initial Authorization Criteria:

- 1. Acute Bacterial Skin and Skin Structure Infection (ABSSSI):
 - Must have documentation of a diagnosis of an acute bacterial skin and skin structure infection caused by a gram-positive organism AND
 - Must have recent culture and sensitivity report to confirm susceptibility to Dalvance AND
 - Trial and failure with all oral antibiotics that the organism is susceptible OR documented allergy or contraindication to all oral antibiotics that the organism is susceptible AND
 - Trial and failure with IV Vancomycin and IV Daptomycin OR culture and sensitivity report that indicates resistance to Vancomycin and Daptomycin

B. <u>Approved Dosing:</u>

- Single Dose Regimen: 1500mg administered IV over 30 minutes OR
- Two Dose Regimen: 1,000mg administered as a single dose and 500mg administered one week later
- C. Must be prescribed at a dose within the manufacturer's dosing guidelines (based on diagnosis, weight, etc) listed in the FDA approved labeling.
- D. Dalvance will be considered investigational or experimental for any other use and will not be covered.
- E. Reauthorization Criteria:



Not applicable – each occurrence requires a new prior authorization

Limitations:

Length of Authorization (if above criteria met)		
Initial Authorization	1 month	
Reauthorization	N/A	

Codes:

Code	Description
J0875	Injection, dalbavancin, 5 mg

REFERENCES

1. Dalvance [package insert]. Madison, NJ: Allergan USA, Inc.; July 2021.

REVIEW HISTORY

DESCRIPTION OF REVIEW / REVISION	DATE APPROVED
Annual review	02/2022
Addition of dosing requirements	12/2021
P&T Review	11/2021
New Policy	09/2021

